Eli Lilly and Company (NYSE:LLY) Holdings Trimmed by Capitol Family Office Inc.

Capitol Family Office Inc. reduced its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 24.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 2,328 shares of the company's stock after selling 736 shares during the quarter. Eli Lilly and Company makes up 2.7% of Capitol Family Office Inc.'s portfolio, making the stock its 9th biggest position. Capitol Family Office Inc.'s holdings in Eli Lilly and Company were worth $1,923,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of LLY. Patron Partners LLC grew its stake in Eli Lilly and Company by 4.4% during the 1st quarter. Patron Partners LLC now owns 3,718 shares of the company's stock worth $3,071,000 after buying an additional 157 shares during the last quarter. Confluence Wealth Services Inc. boosted its holdings in shares of Eli Lilly and Company by 17.3% during the first quarter. Confluence Wealth Services Inc. now owns 10,315 shares of the company's stock valued at $8,555,000 after acquiring an additional 1,521 shares during the period. Bordeaux Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 84.2% during the first quarter. Bordeaux Wealth Advisors LLC now owns 2,199 shares of the company's stock worth $1,816,000 after acquiring an additional 1,005 shares during the last quarter. Heirloom Wealth Management increased its holdings in shares of Eli Lilly and Company by 3.3% in the 1st quarter. Heirloom Wealth Management now owns 9,042 shares of the company's stock worth $7,468,000 after acquiring an additional 286 shares during the period. Finally, Tsfg LLC lifted its position in Eli Lilly and Company by 7.4% in the 1st quarter. Tsfg LLC now owns 766 shares of the company's stock valued at $633,000 after purchasing an additional 53 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on LLY shares. Guggenheim restated a "buy" rating and issued a $936.00 target price on shares of Eli Lilly and Company in a research report on Friday, June 20th. Morgan Stanley reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price on the stock. UBS Group reduced their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Wall Street Zen lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Saturday. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.61.

Eli Lilly and Company Price Performance

NYSE:LLY traded up $3.90 during trading hours on Monday, reaching $779.35. 3,039,950 shares of the company's stock were exchanged, compared to its average volume of 3,681,016. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The company has a market capitalization of $738.62 billion, a P/E ratio of 63.41, a price-to-earnings-growth ratio of 1.13 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The business's 50-day simple moving average is $780.19 and its two-hundred day simple moving average is $800.08.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The business's revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.58 earnings per share. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.77%. Eli Lilly and Company's payout ratio is presently 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.